Objective To study the clinical effects of carbachol on human leukocyte antigen DR ( HLA-DR) in CD+14 rnonocytes from patients with severe sepsis. Methods A total of 100 cases of patients with severe sepsis were divided into two groups including the treatment, group with 60 and control group with 40. The treatment group was intramuscularly administrated with carbachol al the liose of 0. 2 mg· kg-1 for 7 days on the basis of conventional therapy. While the control group was given with placebo at the same time based on routine treatment. Then the proportion of HLA-DR in CD-12 monocyles and CD+4 ,CD+8 T tell subsets were investigated before and after treatment. Results The levels of HLA-DR in CD+14 monocytes and CD+4 ,CD+8 T cells were significantly increased by earbachol, which were (36. 30±13. 14)% , (40. 81 ± 12. 09)% , (31. 14±3. 63)% .respectively. Conclusion Carbachol can regulate inflammatory reaction status of the body and benefit for the immune function of patients with severe sepsis.%目的 研究卡巴胆碱对严重脓毒症患者CD14+单核细胞人类白细胞抗原DR(HLA-DR)的影响及临床意义.方法 严重脓毒症患者100例,分为治疗组60例,对照组40例.治疗组在常规治疗基础上给予卡巴胆碱肌内注射,每次0.2 mg·kg-1,持续7d,对照组常规治疗的同时给予安慰药.观察治疗前后CD14+单核细胞HLA-DR和T细胞亚群CD4+、CD8+百分率的变化.结果 卡巴胆碱治疗后CD14+单核细胞HLA-DR及CD4+、CD8+细胞明显上升,分别为(36.30±13.14)％,(40.81±12.09)％,(31.14±3.63)％(均P＜0.05).结论 卡巴胆碱可以调节机体炎症反应状态,有助于改善严重脓毒症患者的免疫功能.
展开▼
